Neko Health Secures $700M to Revolutionize Health Assessment with Body-Scanning Tech

TL;DR

• $700M Series C Funding: Neko Health, co-founded by Spotify CEO Daniel Ek, secured a $700 million Series C round led by Lightspeed Venture Partners, pushing its valuation to nearly $7 billion.
• US Launch Plans: The startup will deploy the capital to open its first U.S. clinics in New York and other cities later in 2026, marking its expansion beyond Sweden and the UK.
• Innovative Tech: Neko’s core offering combines in-house developed full-body medical scans with bloodwork to deliver comprehensive, preventive health assessments aimed at early disease detection.

A $7 Billion Leap for Preventive Care

Stockholm-based health technology company Neko Health has officially closed a massive $700 million Series C funding round, cementing its status as a leader in the preventive healthcare sector. The round, announced on Wednesday, July 15, 2026, was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners, with significant participation from existing investors like Atomico, General Catalyst, and Lakestar, alongside new backers including Liberty City Ventures and BDT & MSD.

This hyper-capitalized round propels Neko Health to a valuation of nearly $7 billion, representing a staggering fourfold increase from its $1.7 billion valuation just a year prior during its Series B in January 2025. The funding is strategically timed to support the company’s imminent entry into the United States, with its first flagship clinics set to open in Manhattan and other major cities later this year.

The Vision: Redefining Preventive Healthcare

Founded by Spotify CEO Daniel Ek and Hjalmar Nilsonne, Neko Health was built on the premise of shifting healthcare from reactive treatment to proactive prevention. The company aims to redefine how individuals understand and act on their health by providing accessible, comprehensive data before symptoms arise.

"The fundraise follows a $260m Series B in January 2025," marking a period of explosive growth for the startup as it scales its infrastructure to meet a global demand for early disease detection. With an active international waitlist of 350,000 people, Neko is deploying this capital to fuel its "across-the-pond" expansion, aiming to make its preventive scanning clinics a standard part of the US healthcare landscape.

Inside the Technology: Body Scans + Bloodwork

Neko Health’s competitive edge lies in its proprietary, in-house developed full-body medical scanning technology. Unlike competitors that rely on third-party hardware, Neko builds its scanning capabilities internally, allowing for rapid, cost-effective feature upgrades and a more integrated diagnostic experience.

The company’s assessment model is comprehensive, combining these advanced body scans with traditional bloodwork. This dual-approach provides a holistic view of a patient’s health, enabling the early detection of diseases and offering actionable insights for preventive care. By integrating these technologies, Neko aims to provide a "comprehensive health assessment" that goes beyond standard check-ups, identifying potential health risks with greater precision.

An Elite Backing Coalition

The $700 million round attracted an elite tier of global technology leaders and celebrity builders, signaling strong confidence in Neko’s trajectory. Notable new and existing investors include Mark Zuckerberg and Priscilla Chan, who have backed the company alongside tech innovator Tim Ferriss, tennis star Maria Sharapova, musician will.i.am, and OpenAI.

The investment circle also includes high-profile figures like footballer Thierry Henry and new venture partners Positive Sum and BDT & MSD. As part of the round, David Ofer of O.G. Venture Partners will join Neko’s Board of Directors, subject to regulatory approval, further strengthening the company’s strategic leadership.

Strategic Expansion and Future Outlook

The primary objective of this funding is to scale Neko’s operations for its US launch. The company plans to open its inaugural flagship preventive scanning clinic in New York later in 2026, marking its first move outside the UK and Sweden. This expansion is critical for Neko to capture the massive US market, where demand for preventive health solutions is surging.

Neko Health’s rapid valuation growth—from $1.8 billion in early 2025 to nearly $7 billion in mid-2026—demonstrates the market’s appetite for its innovative model. With the backing of Lightspeed Venture Partners and a board increasingly populated by industry veterans, Neko is positioned to become a dominant force in the global preventive health technology sector, turning the promise of early disease detection into a scalable reality.

AndroGuider Team

Articles written by the AndroGuider team. We try to make them thorough and informational while being easy to read.